Showing 8231-8240 of 21409 results for "".
Novel Treatments for Diabetes
https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/novel-treatments-for-diabetes/1787/Dr. Lazar discusses exciting new innovations in our approach to both type I and type II diabetes including Islet cell transplantation, medications for beta cell preservation and new insights into the control of obesity.The Case for Pancreas-After-Kidney Transplantation in Type 1 Diabetics
https://reachmd.com/programs/advances-in-transplantation/the-case-for-pancreas-after-kidney-transplantation-in-type-1-diabetics/6379/Although most patients with type 1 diabetes are able to rely on insulin to effectively manage their condition, sometimes insulin is not enough. When should these patients consider pancreas and/or kidney transplant? Dr. Jonathan Fridell, surgical director of the pancreas transplant program at IndianaDiabetic Retinopathy: Types, Causes, and Associated Somatic Changes
https://reachmd.com/programs/revealing-retina/diabetic-retinopathy-types-causes-and-associated-somatic-changes/5625/The eyes can yield clues to vascular issues elsewhere in the body. How can the two forms of diabetic retinopathy, which are non-proliferative and proliferative, affect vision, and how might retinopathy be associated with somatic effects resulting from diabetes? Dr. Alan Ruby, opthamologist and cliniRisk of RVO in Type 2 Diabetes: GLP-1 Receptor Agonists Versus DPP-4 Inhibitors
https://reachmd.com/programs/eye-on-ocular-health/risk-of-rvo-in-type-2-diabetes-glp-1-receptor-agonists-versus-dpp-4-inhibitors/37663/Among patients with type 2 diabetes, retinal vein occlusion (RVO) is a significant clinical challenge, as well as a leading cause of irreversible vision loss. With vascular health at the center of diabetes management, the choice of glucose-lowering therapy may influence ocular outcomes. Join Dr. MimGastric Banding for Remission of Type 2 Diabetes
https://reachmd.com/programs/focus-on-diabetes/gastric-banding-for-remission-of-type-2-diabetes/3823/There is mounting evidence that surgery can be a key weapon against diabetes, improving glycemic control or sending the disease into remission entirely. As the scourge of diabetes continues across our country and abroad, safety and efficacy of surgery are two legitimate concerns. How does gastric baCatering Drug Therapies To Specific Subsets of Patients with Type 2 Diabetes
https://reachmd.com/programs/diabetes-discourse/catering-drug-therapies-to-specific-subsets-of-patients-with-type-2-diabetes/6387/Treatment regimens for diabetes and obesity are merging. Healthcare professionals are taking a new view to the management of diabetes including rearranging diabetes medication regimens from a glucose control and weight-neutral perspective. What do healthcare professionals need to know to help theirMeal Time Interventions for Patients with Type 2 Diabetes
https://reachmd.com/programs/diabetes-discourse/meal-time-interventions-for-patients-with-type-2-diabetes/6290/Patients on insulin therapy require personalized approaches to their mealtime intervention. What are the choices for patients who need something more to control glucose after meals? Join host Dr. Steven Edelman and his guest, professor of medicine at the Oregon Health & Science University, Dr. MFINE-ONE Across the Ages: Evaluating nsMRA Evidence in CKD and Type 1 Diabetes
https://reachmd.com/clinical-practice/diabetes-and-endocrinology/fine-one-across-the-ages-evaluating-nsmra-evidence-in-ckd-and-type-1-diabetes/70662/Explore FINE-ONE data on the efficacy and safety of finerenone by age in patients with CKD and type 1 diabetes.Real-World Evidence: Effectiveness of Finerenone in Reducing UACR in Patients With CKD and Type 2 Diabetes
https://reachmd.com/clinical-practice/diabetes-and-endocrinology/real-world-evidence-effectiveness-of-finerenone-in-reducing-uacr-in-patients-with-ckd-and-type-2-diabetes/70663/Examine FIRST 2.5 real-world evidence on finerenone and UACR reduction in U.S. patients with CKD and type 2 diabetes.Oral GLP-1 RA Therapy in Type 2 Diabetes and High Cardiovascular Risk
https://reachmd.com/programs/cme/oral-glp-1-ra-therapy-in-type-2-diabetes-and-high-cardiovascular-risk/57051/The 2026 ADA Standards of Care recommend GLP-1 RAs with demonstrated cardiovascular benefit as part of comprehensive management for patients with type 2 diabetes who have established ASCVD, CKD, or multiple cardiovascular risk factors—irrespective of glycemic control needs or current diabetes regime